We have developed a prototype for new eHealth solution. This can simulate what happens in the human body in response to basic interventions: exercise, change in diet, and certain medications. The world-unique aspect of our simulations is that they describe the interplay between detailed organ models, for almost all of the main organs in the human body. These models are transferred to a backend platform. This backend stands in communication with two frontend prototypes: one for in-depth simulations in connection to e.g. teaching, or conversations with a doctor or teacher, and one for usage in a home environment, to help keep goals regarding training, diets, etc.
Addressing target audiences and expressing needs
- Collaboration
Partner companies that want to licence our underlying digital twin technology. This can e.g. be other companies that develop their own eHealth solutions, and want to have a digital twin as a part of their technology. They can in such situations connect to our digital twin backend. Other possible users are e.g. drug development companies, which can use our models to help interprete their data, and aid drug development in all four phases: i) mechanism and target identification, ii) translation to humans, iii) approval, iv) sales.
- Public or private funding institutions
- Research and Technology Organisations
R&D, Technology and Innovation aspects
We have a prototype for a backend, and two different frontends. This is currently being validated in clinical studies (regarding the predictions of the models), and will later this year be tested on real patients (regarding preventive health conversations). The spin-off company is already hiring people, and is used by pharma companies. Other companies, e.g. in the organoid and wearable sensor sectors are currently in discussion with us, for licencing of our digital twin backend technology
The backend technology can readily be scaled to numerous different front-ends. This is currently being exploited in the recently funded STRATIF-AI EU project.
All our organ and whole-body models have been published in scientific journals, including comparison wtih data, both for model training, and for validation, using data not used for training of the models.
The consultancy we already do w.r.t pharma is sustainable, since they have an ongoing and growing interest in acquiring this service.
The sales and licencing of the eHealth technology is an ongoing and growing need, by numerous potential customers, which has a huge potential market.
- Europe
